178 related articles for article (PubMed ID: 35439353)
1. Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients.
Mansell H; Shoker A; Alcorn J; Fenton ME; Tam JS; Semchuk W; Bashir B; Kraft WK; Yao S; Douketis JD
Clin Transl Sci; 2022 Jul; 15(7):1687-1697. PubMed ID: 35439353
[TBL] [Abstract][Full Text] [Related]
2. Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers.
Bashir B; Stickle DF; Chervoneva I; Kraft WK
Clin Transl Sci; 2018 Nov; 11(6):590-596. PubMed ID: 29972633
[TBL] [Abstract][Full Text] [Related]
3. Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant.
Meaney CJ; Sudchada P; Consiglio JD; Wilding GE; Cooper LM; Venuto RC; Tornatore KM
J Clin Pharmacol; 2019 Oct; 59(10):1351-1365. PubMed ID: 31062373
[TBL] [Abstract][Full Text] [Related]
4. Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients.
Wu FL; Tsai MK; Chen RR; Sun SW; Huang JD; Hu RH; Chen KH; Lee PH
Pharmacotherapy; 2005 May; 25(5):646-53. PubMed ID: 15899725
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
Hulskotte E; Gupta S; Xuan F; van Zutven M; O'Mara E; Feng HP; Wagner J; Butterton J
Hepatology; 2012 Nov; 56(5):1622-30. PubMed ID: 22576324
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of apixaban in patients undergoing pancreaticoduodenectomy (PAP-UP).
Zheng R; Lam E; Altshuler P; Crutcher M; Lavu H; Yeo CJ; Stickle D; Leiby B; Kraft WK
Int J Clin Pharmacol Ther; 2024 Apr; ():. PubMed ID: 38660886
[TBL] [Abstract][Full Text] [Related]
7. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients.
Bergmann TK; Isbel NM; Barraclough KA; Campbell SB; McWhinney BC; Staatz CE
Clin Drug Investig; 2014 Mar; 34(3):183-8. PubMed ID: 24385281
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
[TBL] [Abstract][Full Text] [Related]
10. [Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction].
Cofán F; Gutiérrez R; Beardo P; Campistol JM; Oppenheimer F; Alcover J
Nefrologia; 2002; 22(5):470-6. PubMed ID: 12497749
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.
Monchaud C; Marquet P
Clin Pharmacokinet; 2009; 48(7):419-62. PubMed ID: 19691367
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
[TBL] [Abstract][Full Text] [Related]
13. Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients.
Emoto C; Vinks AA; Fukuda T
Ther Drug Monit; 2016 Oct; 38(5):607-13. PubMed ID: 27310200
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
15. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.
Kahvecioglu S; Ersoy A; Gullulu M; Dirican M
Exp Clin Transplant; 2014 Aug; 12(4):334-42. PubMed ID: 24447269
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study.
Rostaing L; Christiaans MH; Kovarik JM; Pascual J
Ann Transplant; 2014 Jul; 19():337-45. PubMed ID: 25017487
[TBL] [Abstract][Full Text] [Related]
17. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
18. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
[TBL] [Abstract][Full Text] [Related]
20. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
Naito T; Mino Y; Otsuka A; Ushiyama T; Ito T; Ozono S; Kagawa Y; Kawakami J
J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
